- Psyched Wellness (PSYC) is reporting a recent positive study into its lead compound
- KGK, a licensed Contract research organization in Canada, has completed the last study on the safety and efficacy of Amanita Muscaria extract (AME-1) extract
- The result of the study shows that AME-1 alone or in combination with ethanol did not impair any learning or memory state, motor coordination, balance, or altered behavioural activity
- Psyched Wellness (PSYC) opened trading at C$0.06 per share
Psyched Wellness (PSYC) is reporting a recent positive study into its lead compound.
KGK, a licensed Contract research organization in Canada, has completed the last study on the safety and efficacy of Amanita Muscaria extract (AME-1) extract.
The neurobehavioral study was to evaluate the efficacy and safety of AME-1 alone, and in combination with behavioral tests. All of the tests were designed to look at behavioural despair, memory, and learning, motor coordination, and maintaining balance.
The result of the study shows that AME-1 alone or in combination with ethanol did not impair any learning or memory state, motor coordination, balance, or altered behavioural activity.
Brian Tancowny, a scientific advisor for Psyched Wellness, stated that this further provides information in the toxicological assessment of AME-1.
“The results of this study further increases the knowledge in a scientific setting indicating no negative behavioural and neurological functional changes with the use of AME-1.”
Psyched Wellness is a Canadian health supplements company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom.
Psyched Wellness (PSYC) opened trading at C$0.06 per share.